No abstract

No abstract

Clinical trials will have to show whether deescalation strategies regarding p16-positive carcinomas are supported by the changes made in the TNM staging system. A prospective multicenter study should examine the universal applicability, the appropriateness for all sublocations, as well as the prognostic significance of the current edition.

The authors regret that a transmisson error occurred during the reclassification process which affected 2 of the 255 patients. Figure 1 shows the corrected illustration of the change of UICC stages and Table 1 the corrected statistical analysis of UICC 7th edition: Consequently referring to the 7th edition, 52.9% of the patients were staged UICC IVA followed by UICC III (16.8%) and 80.0% of the tumors being classified UICC I were p16-negative. UICC I increases from 9.8% to 27.5%. In the paragraph "Results e Extranodal extension" the terms "positive" and "negative" were switched. Correct is ENE-negative: OS ¼ 92.9%, ENE positive: OS ¼ 68.0%, p ¼ 0.008. Fig. 1. Illustration of the change of UICC stages I-IV reclassified according to 8th edition of the UICC.

No abstract